GlassScriptPhysician profile
Brandon Chuang
NPI 1992209373
$2,603.21
in general payments reported to CMS, 2019-2025
18 companies · $203 in 2025
The $203 reported for 2025 was less than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $24.52 · 2022: $53.91 · 2023: $1,135 · 2024: $1,187 · 2025: $203.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,525.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,524.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $571.88 | 2023-2025 | Rocklatan, Hydrus Microstent, Clareon |
| Abbvie INC. | $373.07 | 2022-2025 | Lumigan, Alphagan P, Xen Glaucoma Treatment System |
| Glaukos Corporation | $342.41 | 2023-2025 | Photrexa, Ce-Marked Kxla System, Idosetr |
| Mallinckrodt Hospital Products INC. | $246.36 | 2023-2024 | Acthar |
| Sight Sciences, INC. | $177.38 | 2023-2024 | Tearcare System, Omni Surgical System |
| Oyster Point Pharma, INC. | $171.56 | 2022-2024 | Tyrvaya, Ryzumvi |
| Bausch & Lomb Americas INC. | $149.75 | 2023-2024 | Vyzulta, Miebo |
| Dompe US, INC. | $125.27 | 2023 | Oxervate |
| Biotissue Holdings INC. | $123.63 | 2024 | |
| Thea Pharma INC. | $69.44 | 2023-2024 | Iyuzeh |
| Rxsight INC | $59.24 | 2024-2025 | Rxsight Injector Handpiece, Rxsight Light Delivery Device (Ldd), Rxsight Injector Cartridge |
| Sun Pharmaceutical Industries INC. | $35.42 | 2023 | Cequa |
| Tarsus Pharmaceuticals, INC. | $35.08 | 2024 | Xdemvy |
| Harrow Eye, LLC | $28.90 | 2024 | Iheezo |
| Beaver-Visitec International, INC. | $26.10 | 2025 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb, A Division of Bausch Health US, LLC | $24.52 | 2019 | |
| Ani Pharmaceuticals, INC. | $24.18 | 2024 | Purified Cortrophin Gel |
| Eyevance Pharmaceuticals LLC | $19.02 | 2023 | Flarex |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brandon Chuang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.